Coinbase CEO Brian Armstrong Launches Startup to Extend Lifespan

Brian Armstrong, the CEO of Coinbase Global Inc. (NASDAQ:COIN), announced on October 30, 2023, that his new longevity startup, NewLimit, is dedicated to extending human lifespan by focusing on the treatment of age-related diseases. In a post on X, formerly known as Twitter, Armstrong shared insights into the company’s mission, highlighting the potential to restore the youthful function of cells, thereby improving overall healthspan.

The concept behind NewLimit stems from the correlation between aging and various major diseases. Armstrong emphasized that if the cellular functions could be rejuvenated, it would lead to a significant reduction in the onset of conditions typically associated with aging. “The thing that got me excited about that was like all these major diseases are correlated with aging,” he stated during a recent podcast episode featuring Rick Robin.

Funding and Valuation of NewLimit

Founded in 2021, NewLimit has quickly gained traction in the biotech sector. The startup successfully raised $45 million in funding in October 2023, just five months after completing its Series B round. This latest funding round values NewLimit at an impressive $1.62 billion. The company indicated that this fresh capital will enable the initiation of clinical studies within the next few years, marking an important milestone in their research efforts.

The race to extend human lifespan is intensifying, with various entities exploring innovative solutions. For instance, Sam Altman, CEO of OpenAI, invested $180 million in Retro Biosciences, a company focused on creating a scalable and cost-effective solution for aging. According to a December report by STAT News, Retro Biosciences is pursuing a valuation of $5 billion.

The Current Landscape of Anti-Aging Investments

Despite the optimistic outlook surrounding longevity research, the market for anti-aging and longevity companies has faced challenges. In 2025, shares of several firms in this sector experienced significant declines. For example, Klotho Neurosciences Inc. (NASDAQ:KLTO) saw a decrease of 40.48%, with shares priced at $0.32. Similarly, Telomir Pharmaceuticals Inc. (NASDAQ:TELO) dropped by 64.78%, trading at $1.49, while Longevity Health Holdings Inc. (OTCQB:XAGE) suffered a staggering 97.96% decline, with shares at $0.30.

As the field of longevity research continues to evolve, NewLimit’s efforts may contribute significantly to the understanding of aging and the development of therapies aimed at enhancing healthspan. Armstrong’s commitment to this venture could have far-reaching implications for the future of biotechnology and human health.

In conclusion, the advancements made by NewLimit and similar startups reflect a growing interest in extending not just lifespan but also the quality of life as people age. With substantial financial backing and a clear vision, Armstrong and his team are poised to make a notable impact in this dynamic field.